In-hospital course of patients with heart failure with improved ejection fraction in the DELIVER trial.
Maria A PabónMuthiah VaduganathanBrian L ClaggettSafia ChaturSara SiqueiraPablo Marti-CastelloteRudolf A de BoerAdrian F HernandezSilvio E InzucchiMikhail N KosiborodCarolyn S P LamFelipe MartinezSanjiv J ShahAkshay S DesaiPardeep S JhundJohn J V McMurrayScott D SolomonOrly VardenyPublished in: European journal of heart failure (2024)
Among patients hospitalized for HF in DELIVER, those with HFimpEF experienced a more adverse in-hospital clinical course, necessitating higher resource utilization beyond standard diuretic therapy compared with patients with HF and LVEF consistently >40%, but had similar in-hospital mortality. Treatment benefits of dapagliflozin were not modified by hospitalization type.